ASK1 is also a potential therapeutic target for treating malignant fibrous histiocytomas, a particularly aggressive form of undifferentiated liposarcoma (Chibon et al., 2004). This evidence concerns the gene MAP3K5 and undifferentiated pleomorphic sarcoma.